FDA’s 2025 New Drug Approvals: Mid-Year Recap
July 15, 2026
"
The first half of 2025 has brought transformative options for individuals facing complex health challenges. Sixteen never-before-approved therapies have cleared regulatory review, offering fresh hope across specialties like immunology, oncology, and pediatric care. These advances include treatments for rare genetic disorders, targeted cancer approaches, and preventive solutions for vulnerable populations.